Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

What this study is testing ClinicalTrials.gov NCT06403761 ↗

Description as written by the study sponsor.

This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D). CagriSema is a new investigational medicine that combines two medicines called cagrilintide and semaglutide. Doctors may not yet prescribe CagriSema. Participants will either get CagriSema, semaglutide, cagrilintide, or a ''dummy'' medicine. Which treatment the participants will get is decided by chance. Participants will get the study medicine together with the current daily diabetes medicine metformin. Participants should not take other medicines for diabetes during the study. The study will last for about 42 weeks.

Treatments tested

• Semaglutide Drug

  Participants will receive once-weekly semaglutide subcutaneously.

• Cagrilintide Drug

  Participants will receive once-weekly cagrilintide subcutaneously.

• Placebo semaglutide Drug

  Participants will receive once-weekly placebo matched to semaglutide subcutaneously.

• Placebo cagrilintide Drug

  Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.